Clinical and laboratory features, disease activity, and outcomes of juvenile systemic lupus erythematosus at diagnosis: a single-center study from southern China

2021 ◽  
Author(s):  
Wengen Li ◽  
Sudong Liu ◽  
Liuming Zhong ◽  
Chao Chen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Southern China ◽  
Single Center ◽  
Systemic Lupus ◽  
Juvenile Systemic Lupus Erythematosus ◽  
Single Center Study ◽  
Laboratory Features ◽  
Center Study

Mortality of patients with systemic lupus erythematosus admitted to the intensive care unit – A retrospective single-center study

2018 ◽  
Vol 32 (5) ◽  
pp. 701-709 ◽  
Author(s):  
Guy Zamir ◽  
Yael Haviv-Yadid ◽  
Kassem Sharif ◽  
Nicola Luigi Bragazzi ◽  
Abdulla Watad ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Lupus Erythematosus ◽  
Single Center ◽  
Systemic Lupus ◽  
Single Center Study ◽  
Center Study

Severe systemic lupus erythematosus in emergency department: a retrospective single-center study from China

2011 ◽  
Vol 30 (11) ◽  
pp. 1463-1469 ◽  
Author(s):  
Yi Chen ◽  
Guang-liang Chen ◽  
Chang-qing Zhu ◽  
Xiaoye Lu ◽  
Shuang Ye ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Emergency Department ◽  
Lupus Erythematosus ◽  
Single Center ◽  
Systemic Lupus ◽  
Single Center Study ◽  
Severe Systemic Lupus Erythematosus ◽  
Center Study

scholarly journals Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Yoshiyuki Abe ◽  
Kurisu Tada ◽  
Ken Yamaji ◽  
Naoto Tamura
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Mycophenolate Mofetil ◽  
Adverse Events ◽  
Lupus Erythematosus ◽  
Japanese Patients ◽  
Discontinuation Rate ◽  
Single Center ◽  
Systemic Lupus ◽  
Single Center Study ◽  
Center Study

Objectives. Mycophenolate mofetil (MMF) is the standard treatment for lupus nephritis. In Japan, it was approved for lupus nephritis in 2015. We investigated its real-world safety and effectiveness in Japanese patients with systemic lupus erythematosus (SLE). Methods. We analyzed the continuation rate, adverse events, and reasons for discontinuation of MMF in Japanese patients with SLE in a retrospective single-center study. We included 119 patients who received MMF from 31 July 2015 to 31 May 2019. To compare demographic and clinical characteristics between groups, the Mann–Whitney U -test was used for nonnormally distributed variables. Categorical variables were compared using Fisher’s exact test. Kaplan–Meier curves were plotted for the discontinuation rate of MMF. Results. Patients consisted of 18 males and 101 females. Thirty-five patients discontinued MMF. The cumulative discontinuation rate was 42.4%. Twenty-nine patients discontinued MMF due to adverse events, and six patients discontinued MMF due to remission of SLE or desire for childbearing. At the time of the last observation, the lupus low disease activity state achievement rate was significantly lower in patients who experienced adverse events than those who did not (64% vs. 35%, P = 0.009 ). We examined the concentration of mycophenolate acid (trough level) in stored frozen serum in 11 patients. Two patients had irreversible complications due to viral meningitis; their trough mycophenolate acid concentrations were 8.3 and 6.3 μg/mL, respectively. Conclusions. Although MMF may be effective in Japanese patients with SLE, physicians should pay attention to infections in patients with high mycophenolate acid concentrations.

Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome

Lupus ◽  
2017 ◽  
Vol 27 (3) ◽  
pp. 514-519 ◽  
Author(s):  
S Sahin ◽  
A Adrovic ◽  
K Barut ◽  
N Canpolat ◽  
Y Ozluk ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Renal Involvement ◽  
Disease Onset ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus ◽  
Juvenile Systemic Lupus Erythematosus ◽  
Laboratory Features

Objectives This paper aims to assess in a retrospective fashion the clinical and laboratory features, severity and outcome of juvenile systemic lupus erythematosus (jSLE) from a referral center in Turkey. Methods We have included all jSLE patients ( n = 92) diagnosed according to the revised American College of Rheumatology 1997 criteria between January 2004 and January 2017. Results The most prevalent clinical feature in our cohort was mucocutaneous manifestations (97.8%), followed by constitutional (81.5%), hematological (59.8%) and musculoskeletal manifestations (56.5%). Renal involvement was observed in 38% ( n = 35) of the patients, whereas biopsy-proven lupus nephritis was detected in 29.3% ( n = 27) of the cohort. Neurologic involvement was seen in 15 (16.3%) individuals. Among the patients positive for anticardiolipin IgM and/or IgG ( n = 11, 12%), only three developed antiphospholipid antibody syndrome. The mean SLEDAI-2K scores at disease onset (10.5 ± 4.8) showed a substantial decrease at last visit (4.3 ± 4.6). One-quarter of the patients (26.1%, n = 24) had damage according to the PedSDI criteria with a mean score of 0.45 ± 1.0 (range 0–7). When the PedSDI damage items were evaluated individually, growth failure was the most frequent damage criterion ( n = 6), followed by seizure ( n = 5). Two patients died during the designated study period of end-stage renal disease. The five-year and 10-year survival rate of our cohort was 100% and 94.4%, respectively. Conclusions Given the lower frequency of nephritis and central nervous system disease and lower basal disease activity and damage scores, we could conclude that children with jSLE in Turkey have a more favorable course compared to Asian and African American children, as expected from Caucasian ethnicity.

Sign in / Sign up

Export Citation Format

Share Document